| Literature DB >> 22185601 |
Anna Romagosa1, Matt Allerson, Marie Gramer, Han Soo Joo, John Deen, Susan Detmer, Montserrat Torremorell.
Abstract
Limited information is available on the transmission and spread of influenza virus in pig populations with differing immune statuses. In this study we assessed differences in transmission patterns and quantified the spread of a triple reassortant H1N1 influenza virus in naïve and vaccinated pig populations by estimating the reproduction ratio (R) of infection (i.e. the number of secondary infections caused by an infectious individual) using a deterministic Susceptible-Infectious-Recovered (SIR) model, fitted on experimental data. One hundred and ten pigs were distributed in ten isolated rooms as follows: (i) non-vaccinated (NV), (ii) vaccinated with a heterologous vaccine (HE), and (iii) vaccinated with a homologous inactivated vaccine (HO). The study was run with multiple replicates and for each replicate, an infected non-vaccinated pig was placed with 10 contact pigs for two weeks and transmission of influenza evaluated daily by analyzing individual nasal swabs by RT-PCR. A statistically significant difference between R estimates was observed between vaccinated and non-vaccinated pigs (p < 0.05). A statistically significant reduction in transmission was observed in the vaccinated groups where R (95%CI) was 1 (0.39-2.09) and 0 for the HE and the HO groups respectively, compared to an Ro value of 10.66 (6.57-16.46) in NV pigs (p < 0.05). Transmission in the HE group was delayed and variable when compared to the NV group and transmission could not be detected in the HO group. Results from this study indicate that influenza vaccines can be used to decrease susceptibility to influenza infection and decrease influenza transmission.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22185601 PMCID: PMC3258204 DOI: 10.1186/1297-9716-42-120
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Transmission parameter estimates and related 95% confidence intervals (CI) for each replicate and overall treatment groups
| GROUP | Replicate | IP1 | β2 (95%CI) | R3 (95%CI) | R4 (95%CI) |
|---|---|---|---|---|---|
| NV | 1 | 4.7 | 1.99 (0.97-3.59) | 9.35 (4-18.7) | |
| NV | 2 | 4.2 | 4.71 (2.20-9) | 19.81 (8.3-41.4) | 10.66 (6.57-16.46)a |
| NV | 3 | 4.6 | 1.85 (0.91-3.29) | 8.51 (3.2-18.3) | |
| HE | 1 | 4 | 0.12 (0.01-0.56) | 0.51 (0.02-2.26) | |
| HE | 2 | 5 | 0.36 (0.13-0.77) | 1.8 (0.47-3.9) | 0.99 (0.39-2.09)b |
| HE | 3 | 3.5 | 0.09 (0.01-0.4) | 0.32 (0.01-3.27) | |
| HE | 4 | 2.4 | 0.53 (0.19-1.15) | 1.27 (0.21-1.74) | |
| HO | 1 | 0 | 2.2310-6 (na-0.52) | 0 | |
| HO | 2 | 0 | 2.2310-6 (na-0.52) | 0 | 0c |
| HO | 3 | 0 | 2.9410-6 (na-0.52) | 0 | |
The number of initial infectious (Io) and susceptible (So) pigs in each replicate were Io = 1 and So = 10, except for HE 4 where the So = 9.
1IP: average duration (days) of the infectious period for the contact pigs.
2β: transmission rate per day.
3Reproduction ratio R by replicate.
4Reproduction ratio R when replicates were combined by group.
a,b,cStatistically significant differences (p < 0.05).
HI titers (reciprocal geometric means) against 4 influenza strains (challenge strain IA04 (β) and the commercial vaccine isolates: XP12H1(γ), XP31H1(δ) and the XP69H3) by group of treatment
| HI titers | ||||||||
|---|---|---|---|---|---|---|---|---|
| Group | IA04 | XP12H1 | XP31H1 | XP69H3 | ||||
| before | necropsy | before | necropsy | before | necropsy | before | necropsy | |
| NV | < 10 | < 10 | < 10 | < 10 | < 10 | < 10 | 15 | 12 |
| HE | 14a | 33b | 307 | 240 | 229 | 82 | 494 | 344 |
| HO | 297 | 360 | 38 | 57 | < 10 | < 10 | < 10 | 21 |
Before contact (- 2 dpc) and at necropsy (i.e. + 7 dpc for the control group/+14 dpc for the vaccinated groups).
a,b Statistically significant differences (p < 0.05).
Figure 1Paired influenza A Multiscreen ELISA s/n values against the nucleoprotein of influenza virus two weeks after vaccination (prior to exposure) and at necropsy (bars represent the mean of s/n values (± SD) to influenza ■ after vaccination, □ at necropsy. Positive s/n < 0.673; negative s/n > 0.673. a,b and z,y Statistically significant differences between paired samples for the NV and HE groups before exposure and at necropsy (p < 0.05).
Number of RT-PCR positive contact pigs, per group of treatment and replicates at the end of the study
| Treatment | Replicate | Positive contact pigs | Total number of contact pigs |
|---|---|---|---|
| Non-vaccinated | 1 | 10 | 10 |
| Control | 2 | 10 | 10 |
| 3 | 10 | 10 | |
| Vaccinated | 1 | 1 | 10 |
| Heterologous | 2 | 5 | 10 |
| 3 | 2 | 9a | |
| 4 | 7 | 10 | |
| 1 | 0 | 10 | |
| Homologous | 2 | 0 | 10 |
| 3 | 0 | 10 | |
a One of the contact pig was removed from the group at 7 dpc.
Figure 2Time to infection curves for the three treatment groups. a,bStatistically significant differences (p < 0.05) Difference between vaccine groups (a) is statistically significant at 90% confidence level (p = 0.101) ● Censored data.
Infectious period from seeder (S) and contact pigs (C) when all replicates were combined by group
| Group | ||||
|---|---|---|---|---|
| NV | S | 3/3 | 5.66 ± 0.58 | - |
| NV | C | 30/30 | 4.50 ± 1.07 | 2.83 ± 1.14 1 |
| HE | S | 4/4 | 5.25 ± 0.5 | - |
| HE | C | 15/40 | 3.50 ± 1.84 | 6.87 ± 4.17 2 |
| HO | S | 3/3 | 4.33 ± 1.53 | - |
| HO | C | 0/30 | 0 | - |
aReplicates from the same treatment were pooled.
bThe average number of days from the first until the last day that influenza virus could be detected from nasal swabs by PCR.
cAverage number of days between exposure and the first sample detected positive.
1, 2Statistically significant differences (p < 0.05).
Figure 3Number of new cases represented as the proportion of 10 000 simulations from the stochastic SIR model with initial values of (S = 10, I = 1, R = 0) for each NV replicate.
Figure 4Cumulative proportion of the number of new cases of 10 000 simulations from the stochastic SIR model with initial values of (S = 10, I = 1, R = 0) for each NV and HE replicate.
Figure 5Number of new cases represented as the proportion of 10 000 simulations from the stochastic SIR model with initial values of (S = 10, I = 1, R = 0) for each HE replicate.